Moore Capital Management LP bought a new stake in shares of Azenta, Inc. (NASDAQ:AZTA – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 61,481 shares of the company’s stock, valued at approximately $1,569,000. Moore Capital Management LP owned approximately 0.14% of Azenta as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd grew its stake in shares of Azenta by 2,067.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company’s stock worth $27,000 after buying an additional 765 shares during the last quarter. State of Wyoming purchased a new position in Azenta during the first quarter valued at $38,000. Osaic Holdings Inc. raised its stake in Azenta by 44.9% during the second quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock valued at $39,000 after buying an additional 385 shares during the last quarter. Rockefeller Capital Management L.P. boosted its holdings in Azenta by 98.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,392 shares of the company’s stock worth $46,000 after acquiring an additional 689 shares in the last quarter. Finally, Allworth Financial LP purchased a new stake in shares of Azenta in the second quarter worth $48,000. 99.08% of the stock is currently owned by hedge funds and other institutional investors.
Azenta Trading Down 0.9%
Shares of AZTA stock opened at $32.65 on Tuesday. Azenta, Inc. has a 12-month low of $15.93 and a 12-month high of $41.73. The stock has a market capitalization of $1.43 billion, a P/E ratio of -11.83 and a beta of 1.36. The firm’s 50 day moving average is $29.14 and its 200 day moving average is $25.18.
Analyst Ratings Changes
Several equities analysts have recently issued reports on the company. Needham & Company LLC lifted their price target on Azenta from $33.00 to $37.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded shares of Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 26th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $41.20.
View Our Latest Report on Azenta
About Azenta
Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.
In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.
Recommended Stories
- Five stocks we like better than Azenta
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
